Table 1.
Patient and Imaging Characteristics
| Characteristic | Value |
|---|---|
| Sex | |
| Men | 26 (59) |
| Women | 18 (41) |
| Age, all patients (y)* | 58 (28–80) |
| Age, men | 60 (34–80) |
| Age, women | 55 (28–72) |
| Body mass index* | 27.5 (17.5–39.1) |
| ECOG status | |
| 0 | 35 (80) |
| 1 | 9 (20) |
| Time from diagnosis to therapy (y) | |
| < 1 | 8 (18) |
| 1 to < 2 | 7 (16) |
| ≥ 2 | 29 (66) |
| No. of metastatic sites | |
| 1 | 15 (34) |
| 2 | 15 (34) |
| 3 | 7 (16) |
| ≥ 4 | 7 (16) |
| Sites of metastasis | |
| Lymph nodes | 28 (64) |
| Lungs | 28 (64) |
| Liver | 13 (30) |
| Subcutaneous tissues | 7 (16) |
| Pleura | 6 (14) |
| Spleen | 5 (11) |
| Retroperitoneum | 4 (9) |
| Muscle | 2 (5) |
| Pancreas | 3 (7) |
| Adrenal | 3 (7) |
| Bone | 2 (5) |
| Bowel or peritoneum | 2 (5) |
| Kidney | 1 (2) |
| Antiangiogenic therapy | |
| Bevacizumab alone | 5 (11) |
| Bevacizumab and interferon | |
| Low-dose interferon | 10 (23) |
| High-dose interferon | 29 (66) |
| Baseline measurements | |
| Hemoglobin (g/dL)* | 13.2 (9.4–16.7) |
| Platelets (K/μL)* | 307 (158–627) |
| Absolute neutrophils (K/μL)* | 5.3 (1.9–11.5) |
| Corrected calcium (mg/dL)* | 9.1 (8.2–9.8) |
| Serum alkaline phosphatase (IU/L)* | 90 (25–306) |
| Serum LDH (IU/L)† | 238 (71–1382) |
| Tumor changes at posttherapy CT | |
| Absolute size change (cm)* | 0.03 (−6.1 to 5.0) |
| Size change (%)* | 2 (−59 to 81) |
| Absolute attenuation change (HU)* | −3 (−63 to 66) |
| Attenuation change (%)* | −7 (−65 to 39) |
| Patient survival | |
| Progression free (y)* | 0.7 (0.1–3.9) |
| Overall (y)* | 1.6 (0.1–6.6) |
Note.—Unless otherwise indicated, data are number, with percentage in parentheses (n = 44). ECOG = Eastern Cooperative Oncology Group.
*
Data are means, with range in parentheses.
†
Data are medians, with range in parentheses.